Arvinas, Inc. (NASDAQ:ARVN) Insider Ian Taylor Sells 9,020 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Arvinas Stock Up 5.5 %

Shares of NASDAQ ARVN opened at $17.67 on Wednesday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -6.38 and a beta of 1.88. The stock’s fifty day simple moving average is $18.41 and its 200 day simple moving average is $22.80. Arvinas, Inc. has a 52-week low of $16.07 and a 52-week high of $51.51.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the business posted ($2.53) EPS. As a group, analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Wall Street Analyst Weigh In

ARVN has been the topic of several research analyst reports. Stifel Nicolaus lowered their price target on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, February 12th. Wedbush reiterated an “outperform” rating and set a $57.00 price target on shares of Arvinas in a research report on Tuesday, February 11th. BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price target (down from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Oppenheimer lifted their price target on Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $60.00.

Institutional Trading of Arvinas

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Arvinas by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock worth $135,389,000 after buying an additional 56,561 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Arvinas by 6.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company’s stock worth $78,656,000 after buying an additional 249,295 shares during the period. RTW Investments LP boosted its position in shares of Arvinas by 19.8% in the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock worth $63,919,000 after buying an additional 551,979 shares during the period. FMR LLC boosted its position in shares of Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after buying an additional 204,317 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after buying an additional 367,343 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.